Challenges in Nuclear Medicine: Innovative Theranostic Tools for Personalized Medicine

Frontiers in Medicine

Françoise Kraeber-Bodéré¹ 

关键词: nuclear medicine;    personalized medicine;    PET imaging;    FDG–;    PET;    targeted therapies;   

DOI  :  10.3389/fmed.2014.00016

学科分类：医学（综合）

来源: Frontiers

【 摘 要 】

Over the past few years, nuclear medicine has undergone impressive growth with the development of positron emission tomography (PET), especially using 18F-fluoro-deoxy-glucose (18FDG), and new approaches in targeted radionuclide therapy. These developments pave the way for personalized medicine by offering practical solutions, especially in oncology, neurology, and cardiology. Novel radiopharmaceuticals targeting relevant biomarkers are powerful patient selection tools for patients who may benefit from targeted therapies, and for early therapeutic response assessment. Moreover, once labeled with beta- or alpha-emitters, radiopharmaceuticals targeting relevant molecular markers expressed by different solid tumors, and hemopathies can be used for radionuclide therapy. The final objective here is to eradicate residual cancer disease by using cytotoxic mechanisms complementary to those of “non-radioactive” therapies. PET imaging and targeted radionuclide therapy then come together in the context of the theranostic approach to adapt injected activity for personalized therapy.

【 授权许可】

CC BY